Immutep (IMMP) Stock Research

Over a week ago

Immutep granted new patent for eftilagimod alfa combination

IMMP

Jul 14, 8:13 AM

Maxim gets more bullish on Immutep, upgrades shares

IMMP

Jun 17, 8:04 AM

Immutep to present positive interim Phase I data for IMP761

IMMP

Jun 4, 9:14 AM

Midday Fly By: Estee Lauder walks from Puig, Imax reportedly explores sale

+25

May 22, 11:59 AM

Largest borrow rate increases among liquid names

May 8, 8:45 AM

Immutep receives noncompliance notification from Nasdaq

IMMP

Apr 30, 9:17 AM

Unusually active option classes on open April 15th

Apr 15, 9:40 AM

Immutep granted Orphan Drug Designation for eftilagimod alfa

IMMP

Apr 15, 8:10 AM

Immutep sees progress from Phase I study of LAG-3 agonist for autoimmune disease

IMMP

Mar 19, 8:20 AM

Immutep just downgraded at Maxim, here's why

IMMP

Mar 13, 12:46 PM

Adobe downgraded, Nio upgraded: Wall Street's top analyst calls

+14

Mar 13, 9:39 AM

Immutep says IDMC recommends discontinuation for TACTI-004 Phase III study

IMMP

Mar 13, 8:07 AM

Immutep just downgraded at Baird, here's why

IMMP

Mar 13, 5:01 AM

Immutep just downgraded at Citizens, here's why

IMMP

Mar 13, 4:44 AM

Immutep initiated with bullish view at Citizens, here's why

IMMP

Feb 17, 4:53 AM

Immutep achieves 50% enrollment in global TACTI-004 Phase III trial

IMMP

Feb 6, 8:02 AM

Immutep reports Q2 cash receipts from customers A$4,000

IMMP

Jan 29, 8:17 AM

Immutep announces update on IMP761 from Phase I study

IMMP

Dec 22, 8:11 AM

Immutep announces progress in global TACTI-004 Phase III, enrollment continues

Dec 16, 8:13 AM

What You Missed On Wall Street On Monday

+33

Dec 8, 4:10 PM

Midday Fly By: IBM to buy Confluent, Paramount goes hostile for Warner Bros.

+32

Dec 8, 11:58 AM

Immutep, Dr Reddy's enters strategic collaboration for Eftilagimod Alfa

Dec 8, 8:15 AM

Immutep to present data from AIPAC-003 Phase II trial

IMMP

Dec 2, 8:14 AM

Immutep announces data from EFTISARC-NEO trial

IMMP

Nov 13, 8:17 AM

Immutep receives EUR 2,588,954 R&D tax incentive from French Government

IMMP

Nov 3, 8:19 AM

Novel LAG-3 Agonist Approach: Immutep's lead product, eftilagimod alpha (efti), is a first-in-class soluble LAG-3 fusion protein that acts as an MHC Class II agonist, differentiating it from traditional LAG-3 blocking antibodies and offering a unique mechanism to stimulate the immune system.

Versatile Combination Therapy Potential: Efti has demonstrated promising results in clinical trials when combined with other immunotherapies (like PD-1 inhibitors) and chemotherapy, suggesting broad applicability across various cancer types and treatment regimens.

Advanced Clinical Development & Data: The company's lead program, efti, is in advanced clinical stages (Phase 2/3), including a registrational trial for NSCLC (TACTI-003), backed by positive data indicating its efficacy and a favorable safety profile.

Clinical Trial Failure Risk: Clinical trials for Immutep's product candidates, such as eftilagimod alpha, may fail to demonstrate efficacy or safety, leading to development delays or termination.

Regulatory Approval Uncertainty: Immutep's drug candidates require stringent regulatory approvals from health authorities, which are unpredictable, time-consuming, and may not be granted.

Funding and Capital Dependence: Immutep is a clinical-stage biotechnology company that relies heavily on its ability to raise additional capital, which may not be available on favorable terms or at all.

Charts

Clinical Trial Failure Risk: Clinical trials for Immutep's product candidates, such as eftilagimod alpha, may fail to demonstrate efficacy or safety, leading to development delays or termination.

Regulatory Approval Uncertainty: Immutep's drug candidates require stringent regulatory approvals from health authorities, which are unpredictable, time-consuming, and may not be granted.